GlaxoSmithKline (GSK) ranks as the 10th largest pharmaceutical in the world. The company made it to the primary listing on the London Stock Exchange and the FTSE 100 Index. As of January 27, 2023, the company has a market capitalization of $71.3 billion and is the 8th largest company on the London Stock Exchange. So, if you are planning to invest in the shares of GSK, you first need to know about the company, its products and its services.
What is GlaxoSmithKline?
GlaxoSmithKline is a world-known healthcare company that researches, develops and manufactures pharmaceutical medicines as well as consumer healthcare and vaccines. It operates through several segments, including Vaccines, Consumer Healthcare, Pharmaceuticals, and Corporate Executive Team (CET).
For Pharmaceutical segments, they are developing medicines, particularly for immune inflammation, respiratory and infectious diseases and oncology. Meanwhile, the Vaccines segment produces adult and pediatric vaccines, including diphtheria, hepatitis A and B, polio, measles, tetanus and whooping cough, mumps and rubella, bacterial meningitis, and typhoid. The Corporate Executive Team (CET) segment is tasked with the management of the business side and activities. GlaxoSmithKline was established in 1715 with headquarters in London, England.
Is It Worth To Buy GSK Shares in 2023?
As the world goes back to normalcy, the Pharmaceuticals sub-industry is looking positive as the demand for medical utilisation and electives is enhanced. Some of the important aspects of pharmaceutical companies like GSK are their COVID-19 therapies, immunology and oncology. As COVID-19 variants continue to multiply and getting injected with the COVID-19 vaccine has become part of our lives, pharmaceutical companies will benefit from the recurring sales. Recently, the FDA recommended that people 50 years old and older must get a 4th dose of booster shot to strengthen their body against COVID-19. We can see that people below 50 years old are also headed on the same path. Overall, GSK stock has a Growth Grade of B, a Value Grade of C and Quality Grade of A.
Choosing to Buy/Sell/Hold GSK Stock
If you are torn between buying, selling or holding on to your GSK stocks, you need to do a good analysis as to how it is graded. If you want to obtain a stock evaluation, you need to gain access to huge amounts of data and knowledge to understand it all. Financial ratios, recent stock movements, and income statements will take a toll on you. Fortunately, there is a robust data suite that can help individual investors on whether they should buy or sell GSK stocks. Using this data suite, you can condense data research in a more actionable and customised way, perfect for investors on various knowledge levels.
Whether you buy GSK stocks or not, will solely depend on your trading goals, allocation and risk tolerance. You must also not forget to evaluate a company’s stock by comparing it against other companies in the same industry. This will help you find the most suitable company to invest in. Take note that risk and losses come along in every investment.